mBio
(Feb 2021)
Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption
Leila B. Giron,
Emmanouil Papasavvas,
Xiangfan Yin,
Aaron R. Goldman,
Hsin-Yao Tang,
Clovis S. Palmer,
Alan L. Landay,
Jonathan Z. Li,
John R. Koethe,
Karam Mounzer,
Jay R. Kostman,
Qin Liu,
Luis J. Montaner,
Mohamed Abdel-Mohsen
Affiliations
Leila B. Giron
The Wistar Institute, Philadelphia, Pennsylvania, USA
Emmanouil Papasavvas
The Wistar Institute, Philadelphia, Pennsylvania, USA
Xiangfan Yin
The Wistar Institute, Philadelphia, Pennsylvania, USA
Aaron R. Goldman
The Wistar Institute, Philadelphia, Pennsylvania, USA
Hsin-Yao Tang
The Wistar Institute, Philadelphia, Pennsylvania, USA
Clovis S. Palmer
The Burnet Institute, Melbourne, Victoria, Australia
Alan L. Landay
Rush University, Chicago, Illinois, USA
Jonathan Z. Li
Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
John R. Koethe
Vanderbilt University, Nashville, Tennessee, USA
Karam Mounzer
Philadelphia FIGHT, Philadelphia, Pennsylvania, USA
Jay R. Kostman
Philadelphia FIGHT, Philadelphia, Pennsylvania, USA
Qin Liu
The Wistar Institute, Philadelphia, Pennsylvania, USA
Luis J. Montaner
The Wistar Institute, Philadelphia, Pennsylvania, USA
Mohamed Abdel-Mohsen
ORCiD The Wistar Institute, Philadelphia, Pennsylvania, USA
DOI
https://doi.org/10.1128/mBio.03444-20
Journal volume & issue
Vol. 12,
no. 1
Abstract
Read online
The likelihood of HIV rebound after stopping antiretroviral therapy (ART) is a combination of the size of HIV reservoirs that persist despite ART and the host immunological and inflammatory factors that control these reservoirs. Therefore, there is a need to comprehensively understand these host factors to develop a strategy to cure HIV infection and prevent viral rebound post-ART.
WeChat QR code
Close
